Global Bruxism Management Market Size study, By Type (Diurnal Bruxism, Nocturnal Bruxism), By Treatment Type (Drugs, Antianxiety Agents, Tranquilizers, Sedatives, Muscle Relaxants, Dental Approaches, Occlusal Splint, Mouth Guard), By Cause (Obstructive Sleep Apnea, Sleep Paralysis, Malocclusion, Gastroesophageal Reflux Disease (GERD), Depression, Anxiety, Others) By Distribution Channel (Institutional Sales, Hospital, Dental Clinic, Retail Sales, Drug Store, Retail Store, Supermarket, Mail Order Pharmacies), and Regional Forecasts 2022-2028
Global Bruxism Management Market is valued approximately USD XX million in 2021 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2022-2028. Bruxism or teeth grinding refers to repetitive clenching and grinding of Jaws. In this condition patient clench teeth unconsciously while awake or while sleeping. Awake bruxism happens due factors such as anxiety, stress, anger, frustration, and tension. Whereas Sleep bruxism is associated with sleep arousals. Growing prevalence of neurological disorders and increasing cases of sleep apnea are key drivers for growth of Bruxism Management Market. For instance, according to Pan American Health Organization - In 2019, in United States, Neurological conditions account for around 533,172 deaths. Further, 213,129 (40%) men lost their life , and 320,043 (60%) women died due to neurological conditions. Furthermore, as per Parkinson’s Foundation- In 2020, around 930,000 people in the U.S. were diagnosed with Perkinson’s disease and this number is projected to increase to 1.2 million by 2030. Also, growing healthcare spending in emerging markets and rising pediatric population are anticipated to act as a catalyzing factor for the market demand during the forecast period. However, high treatment cost associated with Bruxism hinders the growth of the market over the forecast period of 2022-2028.
The key regions considered for the global Bruxism Management Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is the leading region across the world in terms of market share owing to rising prevalence of stress and anxiety related diseases and presence of leading market players in the region . Whereas, Asia Pacific is anticipated to exhibit a significant growth rate over the forecast period 2022-2028. Factors such as rising healthcare industry in the emerging countries and growing instances of neurological disorders in the region, would create lucrative growth prospects for the Bruxism Management market across the North American region.
Major market players included in this report are:
F. Hoffmann-La Roche AG
GlaxoSmithKline plc
Eli Lilly and Company
Mayne Pharma
Cadila Pharmaceuticals
Teva Pharmaceutical Industries Ltd.
Pfizer
Endo International plc
Akervall Technologies, Inc.
Mylan N.V.
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Type
Diurnal Bruxism
Nocturnal Bruxism
By Treatment Type
Drugs
Antianxiety Agents
Tranquilizers
Sedatives
Muscle Relaxants
Dental Approaches
Occlusal Splint
Mouth Guard
By Cause
Obstructive Sleep Apnea
Sleep Paralysis
Malocclusion
Gastroesophageal Reflux Disease (GERD)
Depression
Anxiety
Others
By Distribution Channel
Institutional Sales
Hospital
Dental Clinic
Retail Sales
Drug Store
Retail Store
Supermarket
Mail Order Pharmacies
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World
Furthermore, years considered for the study are as follows:
Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028
Target Audience of the Global Bruxism Management Market in Market Study:
Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors
Companies Mentioned
F. Hoffmann-La Roche AG
GlaxoSmithKline plc
Eli Lilly and Company
Mayne Pharma
Cadila Pharmaceuticals
Teva Pharmaceutical Industries Ltd.
Pfizer
Endo International plc
Akervall Technologies, Inc.
Mylan N.V.
Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook